Actively Recruiting
Study of Double-Dose Third-Generation EGFR-TKI with Bevacizumab and Intrathecal Chemotherapy for Advanced NSCLC Patients with Leptomeningeal Metastasis Progressing After Standard-Dose EGFR-TKI
Led by Second Affiliated Hospital of Nanchang University · Updated on 2026-04-23
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combined treatment for advanced non-small cell lung cancer NSCLC patients who have leptomeningeal metastasis that worsened after standard-dose third-generation EGFR-TKI therapy. This Phase II study aims to assess the effectiveness and safety of a double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy. The study also explores how genetic features in cerebrospinal fluid relate to patient outcomes and predict treatment response after resistance to prior EGFR-TKI therapy. Participants will receive a combination of double-dose oral third-generation EGFR-TKI osimertinib 160mg, furmonertinib 160mg, or almonertinib 220mg daily, intrathecal pemetrexed chemotherapy administered in induction, maintenance, and consolidation phases, and intravenous bevacizumab dosed at 7.5mgkg. The treatment involves initial intensive phases followed by maintenance until disease progression or unacceptable side effects. All drugs are given according to specific schedules and dose adjustments are made based on tolerance and blood counts. Before starting treatment, participants undergo screening including imaging, lab tests, and cerebrospinal fluid exams. During treatment, regular monitoring includes blood tests, electrocardiograms, imaging assessments, and quality of life questionnaires every 4 to 8 weeks. Neurological symptoms and performance status are also tracked. Follow-up continues for safety and survival outcomes for about one year after treatment ends. The main measure is the response rate of leptomeningeal metastasis using RANO-LM criteria.
CONDITIONS
Brief Title
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Research Team
J
jing cai Jing Cai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here